In the BioHarmony Drug Report Database

"Preview" Icon

Dabigatran etexilate

Pradaxa (dabigatran etexilate) is a small molecule pharmaceutical. Dabigatran etexilate was first approved as Pradaxa on 2008-03-17. It is used to treat pulmonary embolism in the USA. It has been approved in Europe to treat replacement arthroplasty and venous thromboembolism. It is known to target prothrombin. Pradaxa’s patents are valid until 2031-01-20 (FDA).

 

Trade Name

 

Pradaxa
 

Common Name

 

dabigatran etexilate
 

ChEMBL ID

 

CHEMBL539697
 

Indication

 

pulmonary embolism, replacement arthroplasty, venous thromboembolism
 

Drug Class

 

Thrombin inhibitors (argatroban type)

Image (chem structure or protein)

Dabigatran etexilate structure rendering